Report Library
All Reports
2015 Chronic Lymphocytic Leukemia (CLL) Pulse #2: Drug Usage and Reimbursement
February 11, 2015
We performed a 5-question survey of 40 hematology-oncology specialists in the U.S. to gauge current prescribing practices and
physician experience with reimbursement for ibrutinib (Imbruvica, PCYC/JNJ) and idelalisib (Zydelig, GILD) for the treatment of patients
with CLL. Topics covered in this survey include:
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
To purchase the CLL survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
- A breakdown of the number of patients who received ibrutinib or idelalisib in the last 3 months, by line of treatment
- A comparison of physician experience/impressions of ibrutinib and idelalisib reimbursement by payers
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
To purchase the CLL survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL |
Additional Resources: